FindTrial
Sign In

Evaluation of anti-IgE antibody therapy in the patients with wheat allergy

Evaluation of anti-IgE antibody therapy in the patients with wheat allergy - Evaluation of anti-IgE antibody therapy in the patients with wheat allergy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000014272
Enrollment
20
Registered
2014-06-16
Start date
2014-06-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wheat allergy

Interventions

Subcutaneous injection of 150 mg of Omalizumab (Novartis Pharma, Japan) once every four weeks, 3 times in all.

Sponsors

Shimane University Hospital
Lead Sponsor
Fujita Health University Tokyo Medical and Dental University Osaka University Hiroshima University Hyogo Prefectural Kakogawa Medical Center National Hospital Organization, Sagamihara National Hospital National Hospital Organization, Fukuoka National Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who had an allergic reaction to wheat within three months, or patients who avoid wheat ingestion because of the high titer of wheat-specific IgE.

Exclusion criteria

Exclusion criteria: Patients who had been administrated of Omalizumab in history, and patients who receive immunosuppressive drugs.

Design outcomes

Primary

MeasureTime frame
To evaluate the sensitization status before and after the therapy using basophil activation test, specific IgE test, and enzyme-linked immunosorbent assay.—

Secondary

MeasureTime frame
Food challenge test before and after the treatment if available.—

Countries

Japan

Contacts

Public ContactYuko Chinuki

Shimane University Hospital Dermatology

ychinuki@med.shimane-u.ac.jp0853-20-2210

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026